Core Scientific Restates Multiple Financials, Discloses Material Weakness in Internal Controls Ahead of CoreWeave Merger Vote
CORZ has more than doubled off its 52-week low of $6.2.
Summary
Core Scientific restated its Q3 2025 financials and prior periods due to a $124.7 million overstatement of property, plant, and equipment, revealing a material weakness in internal controls, with previous financial statements no longer reliable.
Key Events · Legal and Risk Events · CORZ
-
Extensive Financial Restatement
Core Scientific is restating its Quarterly Report for Q3 2025, along with its Annual Report for 2024 and Q1/Q2 2025, due to material errors in previously issued financial statements. These prior statements 'should no longer be relied upon'.
-
Material Weakness in Internal Controls
The restatement stems from an identified material weakness in internal control over financial reporting, specifically related to the accounting for demolition of assets during facility conversions.
-
Significant Overstatement of Assets
The cumulative impact of the corrections includes an overstatement of property, plant and equipment, net, by approximately $124.7 million as of September 30, 2025.
-
Impact on Net Loss
The restatement resulted in a decrease in net loss of $2.6 million for the three months ended September 30, 2025, and $1.8 million for the nine months ended September 30, 2025.
Analysis · CORZ · Crypto Assets
Core Scientific, Inc. has filed an amended Quarterly Report (10-Q/A) for the period ended September 30, 2025, to restate its previously issued financial statements. The company determined that property, plant and equipment was overstated by approximately $124.7 million due to improper capitalization of assets committed to demolition during the conversion of facilities from digital asset mining to high-performance computing colocation. This error impacts financial statements for the year ended December 31, 2024, and interim periods in 2024 and 2025, which can no longer be relied upon. The restatement also led to the identification of a material weakness in internal control over financial reporting. This significant financial correction and disclosure of control deficiencies occur as the company prepares for a crucial shareholder vote on its proposed all-stock merger with CoreWeave, Inc. on October 30, 2025, potentially impacting investor sentiment and confidence in the company's financial integrity during this critical period.
At the time of this filing, CORZ was trading at $16.40 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $6.20 to $23.63. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.